Global Immune Repertoire Sequencing Market, By Product Type (Assay Kits (T-Cell Receptor Kits, and B-Cell Receptor Kits) and Instruments), By Application (Cancer Immunotherapy, Biomarker Discovery, Autoimmune Diseases, Vaccine Development and Efficacy, Transplant Rejection and Tolerance, Infectious Diseases, and Other Applications), By End User (Diagnostic Labs, Biotechnology and Pharmaceutical Companies, Academic and Research Institutes, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 114.3 million in 2017, and is projected to exhibit a CAGR of 5.6% over the forecast period (2018 - 2026), as highlighted in a new report published by .
Increasing cancer research, rising government support for pharmacogenomics based drug discovery, and rising number of development programs in various therapeutic areas including oncology, cardiology, infectious diseases, psychiatry, pain management, among others are major factors expected to drive growth of the immune repertoire sequencing market.
Moreover, various organizations are focusing on developing new solutions to find personalized biomarkers in the immune system for better and earlier diagnosis of a disease, eventually driving growth of the immune repertoire sequencing market. For instance, in 2013, the HudsonAlpha Institute for Biotechnology, U.S., initiated a project that aims to sequence 10,000 individual’s T-cell repertoire on Illumina HiSeq and B-cell repertoire on Roche’s 454 GS FLX for diagnosis of several diseases, including cancers, autoimmune diseases, inflammatory diseases, and infectious diseases.
Manufacturers in the immune repertoire sequencing market are focusing on strategic mergers and acquisitions in order to gain significant market share. For instance, in March 2018, ArcherDX Inc. and Ambry Genetics entered into strategic partnership to provide immune repertoire sequencing services to biopharmaceutical customers. This partnership helped both companies to increase its product portfolio in immune repertoire sequencing segment, globally. Similarly, in January 2018, Thermo Fisher Scientific and Illumina, Inc. announced plan for partnership. This agreement enables Illumina to sell Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing (NGS) platforms.
Browse 38 Market Data Tables and 27 Figures spread through 200 Pages and in-depth TOC on "Immune Repertoire Sequencing Market, By Product Type (Assay Kits {T-Cell Receptor Kits, and B-Cell Receptor Kits}, and Instruments), By Application (Cancer Immunotherapy, Biomarker Discovery, Autoimmune Diseases, Vaccine Development and Efficacy, Transplant Rejection and Tolerance, Infectious Diseases, and Other Applications), By End User (Diagnostic Labs, Biotechnology and Pharmaceutical Companies, Academic and Research Institutes, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to immune repertoire sequencing market, click the link below:
https://www.coherentmarketinsights.com/market-insight/immune-repertoire-sequencing-market-1517
Key Takeaways of the Immune Repertoire Sequencing Market:
- The global immune repertoire sequencing market is expected to expand at a CAGR of 5.6% during the forecast period (2018–2026), owing to increasing research & development and demand for genomic and repertoire sequencing-based research.
- Among product type, the assay kit segment is expected to hold major revenue share in 2026. Various companies are focusing on collaborations activities to develop immune repertoire sequencing-based kits for certain immunotherapy response, which is expected to drive growth of the assay kits segment in the market. For instance, in April 2018, MIODx and DiaCarta entered into an agreement for development of MIODx’s ClonoMap immune repertoire sequencing-based tests, to predict patient response to immunotherapy.
- Major players operating in the global immune repertoire sequencing market include Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.
